News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Zongertinib shows promise in Asians with advanced HER2-mutant NSCLC
18 Jan 2026
byStephen Padilla
Treatment with zongertinib in Asian patients with advanced HER2-mutant nonsmall cell lung cancer (NSCLC), who have received prior systemic therapy, delivers robust efficacy and elicits an acceptable safety profile, consistent with the overall global analysis, reports a China study.
Zongertinib shows promise in Asians with advanced HER2-mutant NSCLC
18 Jan 2026
Tremelimumab plus durvalumab safe as first-line treatment for uHCC patients
17 Jan 2026
byStephen Padilla
The use of single tremelimumab (T) regular interval durvalumab (D), or STRIDE, results in a manageable safety profile in Asian patients with unresectable hepatocellular carcinoma (uHCC), as shown by the preliminary results of the SIERRA study.







